Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration
- PMID: 11166965
- DOI: 10.1016/s0304-3959(00)00382-1
Effects of the potent analgesic enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan on respiration
Abstract
We investigated whether the enkephalin-catabolizing enzyme inhibitors RB101 and kelatorphan, which have been shown to be potent analgesics, depress respiration as do opioid analgesics. Ventilation was measured in cats and rodents by the barometric method, in the awake state and during anesthesia. Tissue distribution of the inhibitors was either generalized (RB101, 40-160 mg/kg i.p.), largely restricted by the blood-brain barrier to the periphery (kelatorphan, 0.7-20 mg/kg i.v.), or restricted to the brainstem (i.c.v. injection of RB101 in the fourth ventricle). RB101 did not affect ventilation in any condition tested, and large doses of kelatorphan produced a naloxone-reversible increase in ventilation and breathing frequency. Thus endogenous opioids released during conditions of normal ventilation do not exert any depressant neuromodulatory effect on this function, even when their extracellular concentrations are increased by peptidase inhibitors. The differential effect of these inhibitors on ventilation and nociception is discussed. We conclude that kelatorphan and RB101 are devoid of respiratory-depressant effects and might be interesting pharmacological alternatives to morphine and other opioid agonists.
Similar articles
-
RB101-mediated protection of endogenous opioids: potential therapeutic utility?CNS Drug Rev. 2007 Summer;13(2):192-205. doi: 10.1111/j.1527-3458.2007.00011.x. CNS Drug Rev. 2007. PMID: 17627672 Free PMC article. Review.
-
Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA receptor antagonist: a c-Fos study in the rat spinal cord.Eur J Pain. 2003;7(3):241-9. doi: 10.1016/S1090-3801(02)00122-2. Eur J Pain. 2003. PMID: 12725847
-
Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.Pain. 1994 Jul;58(1):77-83. doi: 10.1016/0304-3959(94)90186-4. Pain. 1994. PMID: 7970841
-
Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.J Pharmacol Exp Ther. 1992 Apr;261(1):181-90. J Pharmacol Exp Ther. 1992. PMID: 1560364
-
Novel approaches to targeting neuropeptide systems.Trends Pharmacol Sci. 2000 Dec;21(12):475-83. doi: 10.1016/s0165-6147(00)01571-6. Trends Pharmacol Sci. 2000. PMID: 11121837 Review.
Cited by
-
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.Nat Rev Drug Discov. 2012 Apr;11(4):292-310. doi: 10.1038/nrd3673. Nat Rev Drug Discov. 2012. PMID: 22460123 Review.
-
The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.Neuropharmacology. 2023 Mar 1;225:109376. doi: 10.1016/j.neuropharm.2022.109376. Epub 2022 Dec 11. Neuropharmacology. 2023. PMID: 36516892 Free PMC article. Review.
-
Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine.Front Psychiatry. 2019 Jan 18;9:742. doi: 10.3389/fpsyt.2018.00742. eCollection 2018. Front Psychiatry. 2019. PMID: 30713510 Free PMC article. Review.
-
An Effective and Safe Enkephalin Analog for Antinociception.Pharmaceutics. 2021 Jun 22;13(7):927. doi: 10.3390/pharmaceutics13070927. Pharmaceutics. 2021. PMID: 34206631 Free PMC article.
-
RB101-mediated protection of endogenous opioids: potential therapeutic utility?CNS Drug Rev. 2007 Summer;13(2):192-205. doi: 10.1111/j.1527-3458.2007.00011.x. CNS Drug Rev. 2007. PMID: 17627672 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
